Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Pyoderma Gangrenosum
NCT01302795Phase 2Completed
- Sponsor
- University of Zurich
- Start
- Feb 2011
- Primary completion
- Aug 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in pyoderma gangrenosum (PG), sponsored by University of Zurich. Started Feb 2011; status: completed.
02
Drugs
canakinumab
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT01302795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01302795.